Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J0593 · per 1 mg

Inj., lanadelumab-flyo, 1 mg

Products billed under this code include Takhzyro.

Payment limit per 1 mg, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J0593

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Takhzyro Takeda Pharmaceuticals America, Inc. 47783-0645-01 150 $13,251.00
Takhzyro Takeda Pharmaceuticals America, Inc. 47783-0646-01 300 $26,502.00

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $88.34 +$0.124 1 mg Inj., lanadelumab-flyo, 1 mg v1, posted September 17, 2026
3Q26 $88.216 +$1.37 1 mg Inj., lanadelumab-flyo, 1 mg v1, posted September 15, 2026
2Q26 $86.846 −$0.344 1 mg Inj., lanadelumab-flyo, 1 mg v1, posted September 15, 2026
1Q26 $87.19 −$0.094 1 mg Inj., lanadelumab-flyo, 1 mg v1, posted September 15, 2026
4Q25 $87.284 +$0.344 1 mg Inj., lanadelumab-flyo, 1 mg v1, posted September 8, 2026
3Q25 $86.94 +$2.138 1 mg Inj., lanadelumab-flyo, 1 mg v1, posted March 10, 2026
2Q25 $84.802 – 1 mg Inj., lanadelumab-flyo, 1 mg v1, posted March 10, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files